Targeting collagen damage for sustained in situ antimicrobial activities

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Infectious Diseases

Background:

• Antimicrobial peptides (AMPs) show promise as anti-infective agents but face challenges like short retention and off-target effects.
• Current AMP delivery methods struggle with sustained release and targeted action at infection sites.
• Injuries and infections often involve collagen damage, presenting an opportunity for targeted therapeutic strategies.

Purpose of the Study:

• To develop a novel drug delivery strategy for AMPs by immobilizing them to damaged collagen.
• To enhance the efficacy and duration of antimicrobial action of AMPs in infected tissues.
• To investigate the potential of collagen-targeted AMP delivery for wound healing.

Main Methods:

• Conjugation of a dimeric antimicrobial peptide (Feleucin-K3, Flc) with a collagen hybridizing peptide (CHP).
• In vitro and in vivo assessment of the Flc-CHP conjugate's ability to anchor to damaged collagen in infected wounds.
• Evaluation of the conjugate's antimicrobial activity, retention time, and impact on wound healing in a rat model.

Main Results:

• The Flc-CHP conjugate selectively and prolongedly anchored to denatured collagen in infected wounds.
• The dimeric conjugate design maintained the potent, broad-spectrum antimicrobial activity of Flc.
• Enhanced and extended in vivo antimicrobial efficacy and facilitated tissue repair were observed in the rat wound healing model.

Conclusions:

• Targeting collagen damage offers a promising strategy for developing sustained-release antimicrobial peptide delivery systems.
• This approach overcomes key limitations of traditional AMPs, improving their therapeutic potential for infected injuries.
• The developed Flc-CHP conjugate represents a novel platform for treating a wide range of infected tissues by leveraging the body's natural matrix components.